Non-retrieved inferior vena cava filters: causes and long-term follow-up

Ribas, J.; Alba, Esther; Pascual-González, Yuliana; Ruíz, Yolanda; Iriarte, Adriana; Mora-Luján, José María; Valcárcel, J.; Corbella, Xavier; Santos, Salud; Escalante, E.; Riera‐Mestre, Antoni

doi:10.1016/j.ejim.2020.12.026

Cited by 7 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there are some special conditions in which the retrievable filters were not successfully retrievable. IVCF, providing long-term protection from potentially fatal PE, is associated with some severe complications, such as filter thrombosis, filter tilt, vena cava wall penetration, filter migration, filter fracture, recurrent VTE [4][5][6]. Filter thrombosis, a well-documented complication, has a less than 10% incidence rate with contemporary filters but published rates range widely from 2 to 30% [7].…”

Section: Introductionmentioning

confidence: 99%

Outcome of anticoagulation with rivaroxaban in patients with non-retrieved inferior vena cava filters for the prevention of filter thrombosis: a retrospective cohort study

Wang

Jiang

Zhang

et al. 2022

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background Non-retrieved inferior vena cava filter (IVCF) is associated with some severe complications, such as filter thrombosis. The aim of this retrospective cohort study was to evaluate the outcome of rivaroxaban for the prevention of filter thrombosis in patients with non-retrieved IVCF. Methods The study based on the VTE registry databases was limited to patients with non-retrieved IVCF treated at Nanjing Drum Tower Hospital from January 2012 to December 2017. Outcomes included filter thrombosis, total bleeding events, death. Results A total of 202 patients were enrolled in the study and divided into rivaroxaban group and warfarin group. Mean follow-up period of the two groups was 57.4 ± 20.8 and 62.2 ± 23.0 months, respectively. In risk factors for VTE, transient factors (P = 0.008) and history of VTE (P = 0.028) were statistically different between the two groups. A total of 13 (6.4%) patients developed filter complications, of which 4 (3.5%) and 5 (5.7%) patients in rivaroxaban group and warfarin group developed filter thrombosis, respectively, without significant difference (P = 0.690). The total bleeding events in rivaroxaban group, including major bleeding and clinically relevant and non-major (CRNM) bleeding, were significantly lower than that in warfarin group (P = 0.005). Adjusting for hypertension, transient risk factors, history of VTE and cancer, no differences in the hazard ratio for outcomes were notable. Conclusions It is necessary to perform a concomitant anticoagulation in patients with non-retrieved filters. Rivaroxaban can be an alternative anticoagulant option for the prevention of filter thrombosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Outcome of anticoagulation with rivaroxaban in patients with non-retrieved inferior vena cava filters for the prevention of filter thrombosis: a retrospective cohort study

Wang

Jiang

Zhang

et al. 2022

BMC Cardiovasc Disord

View full text Add to dashboard Cite

show abstract

“…Of note, at mean follow-up 2.1 (0.68-4.78, n=112) years Ribas et al found no cases of filter embolization, migration or fracture, but 12.5% had thrombotic complications including: filter thrombosis requiring long-term anticoagulation (4.5%), DVT (4.5%), and IVC thrombotic occlusion (3.6%). These included 57 patients with temporary filters and 55 with permanent filters [ 123 ]. Chow et al confined their single-center observational study to include patients in whom permanent filters were placed, concluding that the permanent filters were effective at preventing recurrent PE but post-filter VTE and post-thrombotic syndrome were common, leading to a high morbidity rate.…”

Section: Reviewmentioning

confidence: 99%

“…In concordance with these results, a recent retrospective study by Rauba et ). These included 57 patients with temporary filters and 55 with permanent filters [123]. Chow et al confined their single-center observational study to include patients in whom permanent filters were placed, concluding that the permanent filters were effective at preventing recurrent PE but post-filter VTE and post-thrombotic syndrome were common, leading to a high morbidity rate.…”

Section: Long-term Indwelling and Complicationsmentioning

confidence: 99%

Inferior Vena Cava Filters and Complications: A Systematic Review

Bajda,

Park,

Raj

et al. 2023

Cureus

View full text Add to dashboard Cite

Inferior vena cava (IVC) filters have been used since the 1960s to treat patients with acute risk of pulmonary embolism (PE) to prevent migration of thrombus by trapping it within the filter. Traditional usage has been in patients with contraindication to anticoagulation that carry a significant mortality risk. In this systematic review, we sought to evaluate complications associated with placement of inferior vena cava filters based on published data from the past 20 years. A search was performed on October 6th, 2022, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for systematic reviews, using three databases (ProQuest, PubMed and ScienceDirect) for articles published between the dates of February 1, 2002 and October 1, 2022. Results were filtered to include full-text, clinical studies, and randomized trials written in English pertaining to keywords “IVC filter AND complications”, “Inferior Vena Cava Filter AND complications”, “IVC filter AND thrombosis” and “Inferior Vena Cava Filter AND thrombosis”. Articles identified by the three databases were pooled and further screened for relevance based on inclusion and exclusion criteria. Initial search results yielded 33,265 hits from all three databases combined. Screening criteria were applied, with 7721 results remaining. After further manual screening, including removal of duplicate hits, a total of 117 articles were selected for review. While there are no consensus guidelines for best practice, there is compelling evidence that IVC filters can provide significant protection against PE with minimal complications if the treatment window is appropriate. Increase in the variety of filter models has led to broader availability, but skepticism remains about their efficacy and safety, with ongoing controversy surrounding appropriate indications. Further research is needed to establish clear guidelines on appropriate indications for IVC placement and to determine time course of complications versus benefits for indwelling filters.

show abstract

“…2,3 Non-retrieval of temporary IVCFs poses patient safety concerns, including risks of IVCF migration, embolization, and thrombosis. 4 Absorbable IVCFs constructed with poly-p-dioxanone (PPDO) eliminate the need for filter retrieval. 5,6 The favorable degradation profile of PPDO IVCFs allows for desired mechanical strength and integrity during the intended dwell time, followed by absorption after the intended use.…”

Section: Introductionmentioning

confidence: 99%

“…2, 3 Non-retrieval of temporary IVCFs poses patient safety concerns, including risks of IVCF migration, embolization, and thrombosis. 4…”

Section: Introductionmentioning

confidence: 99%

Image-guided deployment and monitoring of a novel tungsten nanoparticle–infused radiopaque absorbable inferior vena cava filter in pigs

Valentin

Damasco

Bernardino

et al. 2023

Preprint

View full text Add to dashboard Cite

The use of absorbable inferior vena cava filters (IVCFs) constructed with poly-p-dioxanone (PPDO) eliminates risks and complications associated with the use of retrievable metallic filters. Radiopacity of radiolucent PPDO IVCFs can be improved with the incorporation of nanoparticles (NPs) made of high-atomic number materials such as gold and bismuth. In this study, we focused on incorporating tungsten NPs (WNPs), along with polyhydroxybutyrate (PHB), polycaprolactone (PCL), and polyvinylpyrrolidone (PVP) polymers to increase the surface adsorption of the WNPs. We compared the imaging properties of WNPs with single-polymer PHB (W-P) and WNPs with polymer blends consisting of PHB, PCL, and PVP (W-PB). Our in vitro analyses using PPDO sutures showed enhanced radiopacity with either W-P or W-PB coating, without compromising the inherent physico-mechanical properties of the PPDO sutures. We observed a more sustained release of WNPs from W-PBcoated sutures than W-P-coated sutures. We successfully deployed W-P- and W-PB-coated IVCFs into the inferior vena cava of pig models, with monitoring by fluoroscopy. At the time of deployment, W-PB-coated IVCFs showed a 2-fold increase in radiopacity compared to W-P-coated IVCFs. Longitudinal monitoring of in vivo IVCFs over a 12-week period showed a drastic decrease in radiopacity at week 3 for both filters. Results of this study highlight the utility of NPs and polymers for enhancing radiopacity of medical devices; however, different methods of incorporating NPs and polymers can still be explored to improve the efficacy, safety, and quality of absorbable IVCFs.

show abstract

Non-retrieved inferior vena cava filters: causes and long-term follow-up

Cited by 7 publications

References 25 publications

Outcome of anticoagulation with rivaroxaban in patients with non-retrieved inferior vena cava filters for the prevention of filter thrombosis: a retrospective cohort study

Outcome of anticoagulation with rivaroxaban in patients with non-retrieved inferior vena cava filters for the prevention of filter thrombosis: a retrospective cohort study

Inferior Vena Cava Filters and Complications: A Systematic Review

Image-guided deployment and monitoring of a novel tungsten nanoparticle–infused radiopaque absorbable inferior vena cava filter in pigs

Contact Info

Product

Resources

About